ACOG Practice Bulletin No 39, October 2002. Selective estrogen receptor modulators

International Journal of Gynecology and Obstetrics

Volumn 79, Issue 3, 2002, Pages 289-298

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CENTCHROMAN; CLOMIFENE; DROLOXIFENE; ESTROGEN RECEPTOR; IDOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TIBOLONE; TOREMIFENE;

ABSORPTIOMETRY; ARTICLE; ATROPHY; BONE MASS; BONE METABOLISM; BREAST CANCER; CANCER RISK; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DRUG EFFECT; DYSPAREUNIA; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; HOT FLUSH; HUMAN; INFERTILITY; LEUKORRHEA; MAMMOGRAPHY; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PELVIS FLOOR; POLYP; POSTMENOPAUSE; PRIORITY JOURNAL; SIDE EFFECT; THROMBOEMBOLISM; URINARY TRACT; URINE INCONTINENCE; UTERUS; UTERUS CANCER; UTERUS PROLAPSE; UTERUS SARCOMA; VAGINA ATROPHY; VAGINA BLEEDING; VAGINITIS;

EID: 0036891024     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(02)00350-8     Document Type: Article

References (67)

1. Young RL, Goldzieher JW, Elkind-Hirsch K, Hickox PG, Chakraborty PK. A short-term comparison of the effects of clomiphene citrate and conjugated equine estrogen in menopausal/castrate women. Int J Fertil 1991;36:167-71. (Level I)
2. Modelska K, Cummings S. Tibolone for postmenopausal women: Systematic review of randomized trials. J Clin Endocrinol Metab 2002;87:16-23. (Level III)
3. Hendrix SL, McNeeley SG. Effect of selective estrogen receptor modulators on reproductive tissues other than endometrium. Ann N Y Acad Sci 2001;949:243-50. (Level III)
4. Fleischer AC, Wheeler JE, Yeh IT, Kravitz B, Jensen C, MacDonald B. Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene. J Ultrasound Med 1999;18:503-12. (Level I)
5. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84. (Level I)
6. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-56. (Level I)
7. Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, Somell A, et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 1991;83:1299-306. (Level I)
8. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-47. (Level I)
9. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-51. (Level I)
10. Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995;80:3191-5. (Level I)
11. Guetta V, Lush RM, Figg WD, Waclawiw MA, Cannon RO 3rd. Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women. Am J Cardiol 1995;76:1072-73. (Level I)
12. Mijatovic V, van der Mooren MJ, Kenemans P, de Valkde Roo GW, Netelenbos C. Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: A randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens. Menopause 1999;6:134-7. (Level I)
13. Shewmon DA, Stock JL, Rosen CJ, Heinilouma KM, Hogue MM, Morrison A, et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994;14:1586-93. (Level I)
14. Cattaneo M, Baglietto L, Zighetti ML, Bettega D, Robertson C, Costa A, et al. Tamoxifen reduces plasma homocysteine levels in healthy women. Br J Cancer 1998;77:2264-66. (Level I)
15. Anker G, Lonning PE, Ueland PM, Refsum H, Lien EA. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. Int J Cancer 1995;60:365-68. (Level II-2)
16. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial. J Clin Endocrinol Metab 2000;85:214-8. (Level I)
17. De Leo V, la Marca A, Morgante G, Lanzetta D, Setacci C, Petraglia F. Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am J Obstet Gynecol 2001;184:350-53. (Level I)
18. Cushman M, Costantino JP, Tracy RP, Song K, Buckley L, Roberts JD, et al. Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol 2001;21:255-61. (Level I)
19. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-57. (Level I)
20. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88. (Level I)
21. Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I. Antiatherogenic effects of adjuvant anti-estrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996;14:429-33. (Level I)
22. Gylling H, Pyrhonen S, Mantyla E, Maenpaa H, Kangas L, Miettinen TA. Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer. J Clin Oncol 1995;13:2900-5. (Level I)
23. Herrington DM, Pusser BE, Riley WA, Thuren TY, Brosnihan KB, Brinton EA, et al. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 2000;20:1606-12. (Level I)
24. Herrington DM, Brosnihan KB, Pusser BE, Seely EW, Ridker PM, Rifai N, et al. Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab 2001;86:4216-22. (Level I)
25. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97. (Level I)
26. Davies GC, Huster WJ, Lu Y, Plouffe L Jr, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999;93:558-65. (Level III)
27. Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 2000;95:95-103. (Level I)
28. Fugere P, Scheele WH, Shah A, Strack TR, Glant MD, Jolly E. Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 2000;182:568-74. (Level I)
29. Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994;170:447-51. (Level III)
30. McGonigle KF, Shaw SL, Vasilev SA, Odom-Maryon T, Roy S, Simpson JF. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol 1998;178:1145-50. (Level II-3)
31. Tomas E, Kauppila A, Blanco G, Apaja-Sarkkinen M, Laatikainen T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 1995;59:261-6. (Level I)
32. Kennedy MM, Baigrie CF, Manek S. Tamoxifen and the endometrium: Review of 102 cases and comparison with HRT-related and non-HRT-related endometrial pathology. Int J Gynecol Pathol 1999;18:130-7. (Level II-2)
33. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37. (Level I)
34. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-67. (Meta-analysis)
35. Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino J, Bernstein L, et al. Association of tamoxifen and uterine sarcoma. Clin Oncol 2002;20:2758-60. (Level III)
36. Pyrhonen S, Ellmen J, Vuorinen J, Gershanovich M, Tominaga T, Kaufmann M, et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 1999;56:133-43. (Meta-analysis)
37. Marttunen MB, Cacciatore B, Hietanen P, Pyrhonen S, Tiitinen A, Wahlstrom T, et al. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women. Br J Cancer 2001;84:897-902. (Level I)
38. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45. (Level I)
39. Miodrag A, Ekelund P, Burton R, Castleden CM. Tamoxifen and partial oestrogen agonism in postmenopausal women. Age Ageing 1991;20:52-4. (Level II-2)
40. Bruning PF. Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: Preliminary results of a double-blind dose-finding phase II trial. Eur J Cancer 1992;28A:1404-7. (Level I)
41. Goldstein SR, Neven P, Zhou L, Taylor YL, Ciaccia AV, Plouffe L. Raloxifene effect on frequency of surgery for pelvic floor relaxation. Obstet Gynecol 2001;98:91-6. (Level III)
42. Loprinzi CL, Zahasky KM, Sloan JA, Novotny PJ, Quella SK. Tamoxifen induced hot flashes. Clin Breast Cancer 2000;1:52-6. (Level III)
43. Dowsett M, Dixon JM, Horgan K, Salter J, Hills M, Harvey E. Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. Clin Cancer Res 2000;6:2260-67. (Level I)
44. Haarstad H, Lonning PE, Gundersen S, Wist E, Raabe N, Kvinnsland S. Influence of droloxifene on metastatic breast cancer as first-line endocrine treatment. Acta Oncol 1998;37:365-68. (Level III)
45. Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmen J. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group. Breast Cancer Res Treat 1997;45:251-62. (Level I)
46. Chlebowski RT, Collyar DE, Somerfield MR. Pfister DG. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene. J Clin Oncol 1999;17:1939-55. (Level III)
47. Powles T, Eeles R, Ashley S, Easton D, Chang J, Downsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101. (Level I)
48. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352:93-7. (Level I)
49. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial. Breast Cancer Res Treat 2001;65:125-34. (Level I)
50. Ruffin MT 4th, August DA, Kelloff GJ, Boone CW, Weber BL, Brenner DE. Selection criteria for breast cancer chemoprevention subjects. J Cell Biochem Suppl 1993;17G:234-41. (Level III)
51. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington, DC: NOF; 1999. (Level III)
52. Johnston CC Jr, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: Three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000;160:3444-50. (Level I)
53. Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, et al. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group Osteoporos Int 1999;10:330-6. (Level I)
54. Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, et al. Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial. J Bone Miner Res 1998;13:1747-54. (Level I)
55. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and semm lipid profile in healthy postmenopausal women. J Bone Miner Res 1996;11:835-42. (Level I)
56. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Ames RW, Reid IR. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 1995;99:636-41. (Level I)
57. Prestwood KM, Gunness M, Muchmore DB, Lu Y, Wong M, Raisz LG. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000;85:2197-202. (Level I)
58. Ott SM, Oleksik A, Lu Y, Harper K, Lips P. Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. J Bone Miner Res 2002;17:341-8. (Level I)
59. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41. (Level I)
60. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:985-92. (Level I)
61. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52. (Level I)
62. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis; the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76. (Level I)
63. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17:1-10. (Level I)
64. Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, et al. Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 2000;283:1318-21. (Level I)
65. Berliere M, Charles A, Galant C, Donnez J. Uterine side effects of tamoxifen: A need for systematic pretreatment screening. Obstet Gynecol 1998;91:40-4. (Level II-2)
66. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86. (Level III)
67. Bryant J, Fisher B, Dignam J. Duration of adjuvant tamoxifen therapy. J Natl Cancer Inst Monogr 2001;30:56-61. (Level III)